Increased resting energy expenditure, fat oxidation, and food intake in patients with highly active antiretroviral therapy-associated lipodystrophy

American Journal of Physiology - Endocrinology and Metabolism

Volumn 292, Issue 3, 2007, Pages

  Sutinen, Jussi ^a   Yki Järvinen, Hannele ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Buffalo hump; Calorimetry; Lipoatrophy; Respiratory quotient

Indexed keywords

GLUCOSE; INSULIN; INTERLEUKIN 6; LEPTIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD LEVEL; BODY COMPOSITION; BODY FAT; CALORIC INTAKE; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY EXPENDITURE; FAT INTAKE; FATTY ACID OXIDATION; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; LIPODYSTROPHY; MALE; PRIORITY JOURNAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BASAL METABOLISM; BODY COMPOSITION; CROSS-SECTIONAL STUDIES; EATING; ENERGY METABOLISM; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; MOTOR ACTIVITY;

EID: 33947114833     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00219.2006     Document Type: Article

References (61)

1. Andersen O, Haugaard SB, Andersen UB, Friis-Moller N, Storgaard H, Volund A, Nielsen JO, Iversen J, Madsbad S. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in β-cell function. Metabolism 52: 1343-1353, 2003.
2. Andersson LB. Genes and obesity. Ann Med 28: 5-7, 1996.
3. Asensi V, Martin-Roces E, Carton JA, Collazos J, Maradona JA, Alonso A, Medina M, Aburto JM, Martinez E, Rojo C, Bustillo E, Fernandez C, Arribas JM. Perirenal fat diameter measured by echography could be an early predictor of lipodystrophy in HIV type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis 39: 240-247, 2004.
4. Bahr R, Hansson P, Sejersted OM. Triglyceride/fatty acid cycling is increased after exercise. Metabolism 39: 993-999, 1990.
5. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P, Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026-1031, 2002.
6. Batterham MJ. Investigating heterogeneity in studies of resting energy expenditure in persons with HIV/AIDS: a meta-analysis. Am J Clin Nutr 81: 702-713, 2005.
7. Batterham MJ, Garsia R, Greenop PA. Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy "Diet FRS Study". AIDS 14: 1839-1843, 2000.
8. Beltran S, Lescure FX, Desailloud R, Douadi Y, Smail A, El Esper I, Arlot S, Schmit JL. Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. Clin Infect Dis 37: 579-583, 2003.
9. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112-1115, 1999.
10. Chapplain JM, Beillot J, Begue JM, Souala F, Bouvier C, Arvieux C, Tattevin P, Dupont M, Chapon F, Duvauferrier R, Hespel JP, Rochcongar P, Michelet C. Mitochondrial abnormalities in HIV-infected lipoatrophic patients treated with antiretroviral agents. J Acquir Immune Defic Syndr 37: 1477-1488, 2004.
11. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 13: 2251-2260, 1999.
12. Danforth E Jr, Burger A. The role of thyroid hormones in the control of energy expenditure. Clin Endocrinol Metab 13: 581-595, 1984.
13. Desbuquois B, Aurbach GD. Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassay. J Clin Endocrinol Metab 33: 732-738, 1971.
14. Estrada V, Serrano-Rios M, Larrad MT, Villar NG, Lopez AG, Tellez MJ, Fernandez C. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr 29: 32-40, 2002.
15. Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 37: 287-301, 1988.
16. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 350: 1220-1234, 2004.
17. Gelfand RA, Hutchinson-Williams KA, Bonde AA, Castellino P, Sherwin RS. Catabolic effects of thyroid hormone excess: the contribution of adrenergic activity to hypermetabolism and protein breakdown. Metabolism 36: 562-569, 1987.
18. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 9: 161-177, 2004.
19. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352: 48-62, 2005.
20. Grunfeld C, Pang M, Shimizu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 55: 455-460, 1992.
21. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 51: 1143-1147, 2002.
22. Hammond E, Nolan D, James I, Metcalf C, Mallal S. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 18: 815-817, 2004.
23. Himms-Hagen J. Does brown adipose tissue (BAT) have a role in the physiology or treatment of human obesity? Rev Endocr Metab Disord 2: 395-401, 2001.
24. Hommes MJ, Romijn JA, Endert E, Sauerwein HP. Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. Am J Clin Nutr 54: 311-315, 1991.
25. Jaggy C, von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, Furrer HJ, Telenti A, Battegay M, Flepp M, Vernazza P, Bernasconi E, Hirschel B. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 362: 877-878, 2003.
26. Jan V, Cervera P, Maachi M, Baudrimont M, Kim M, Vidal H, Girard PM, Levan P, Rozenbaum W, Lombes A, Capeau J, Bastard JP. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 9: 555-564, 2004.
27. Jequier E. Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 967: 379-388, 2002.
28. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22: 685-708, 2000.
29. Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, Gertow K, Virkamaki A, Nyman T, Vidal H, Hamsten A, Yki-Järvinen H. Expression of adipogenic transcription factors, peroxisome proliferator- activated receptor γ co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 17: 1753-1762, 2003.
30. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 8: 9-15, 2003.
31. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, Eckel RH. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 15: 1993-2000, 2001.
32. Kosmiski LA, Kuritzkes DR, Sharp TA, Hamilton JT, Lichtenstein KA, Mosca CL, Grunwald GK, Eckel RH, Hill JO. Total energy expenditure and carbohydrate oxidation are increased in the human immunodeficiency virus lipodystrophy syndrome. Metabolism 52: 620-625, 2003.
33. Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 286: E296-E303, 2004.
34. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S, Andersen O. Increased expression of TNF-α, IL-6, and IL-8 in HIV-associated lipodystrophy. Implications for the reduced expression and plasma levels of adiponectin. Am J Physiol Endocrinol Metab 285: E1072-E1080, 2003.
35. Macallan DC, Noble C, Baldwin C, Jebb SA, Prentice AM, Coward WA, Sawyer MB, McManus TJ, Griffin GE. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 333: 83-88, 1995.
36. McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA. Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 89: 4258-4263, 2004.
37. Meininger G, Hadigan C, Laposata M, Brown J, Rabe J, Louca J, Aliabadi N, Grinspoon S. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution. Metabolism 51: 260-266, 2002.
38. Miles J, Classcock R, Aikens J, Gerich J, Haymond N. A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res 24: 96-99, 1983.
39. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 31: 514-520, 2002.
40. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 8: 617-626, 2003.
41. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med 346: 570-578, 2002.
42. Pernerstorfer-Schoen H, Schindler K, Parschalk B, Schindl A, Thoeny-Lampert S, Wunderer K, Elmadfa I, Tschachler E, Jilma B. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS 13: 2389-2396, 1999.
43. Renard E, Fabre J, Paris F, Reynes J, Bringer J. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf) 51: 223-230, 1999.
44. Rodriguez de la Concepcion ML, Domingo JC, Domingo P, Giralt M, Villarroya F. Uncoupling protein 1 gene expression implicates brown adipocytes in highly active antiretroviral therapy-associated lipomatosis. AIDS 18: 959-960, 2004.
45. Schrauwen P, van Marken Lichtenbelt WD, Saris WH, Westerterp KR. Changes in fat oxidation in response to a high-fat diet. Am J Clin Nutr 66: 276-282, 1997.
46. Sekhar RV, Jahoor F, White AC, Pownall HJ, Visnegarwala F, Rodriguez-Barradas MC, Sharma M, Reeds PJ, Balasubramanyam A. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 283: E332-E337, 2002.
47. Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15: 1801-1809, 2001.
48. Sjostrom L, Schutz Y, Gudinchet F, Hegnell L, Pittet PG, Jequier E. Epinephrine sensitivity with respect to metabolic rate and other variables in women. Am J Physiol Endocrinol Metab 245: E431-E442, 1983.
49. Smith SR, de Jonge L, Zachwieja JJ, Roy H, Nguyen T, Rood JC, Windhauser MM, Bray GA. Fat and carbohydrate balances during adaptation to a high-fat. Am J Clin Nutr 71: 450-457, 2000.
50. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16: 2183-2193, 2002.
51. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther 8: 199-207, 2003.
52. Sutinen J, Kannisto K, Korsheninnikova E, Fisher RM, Ehrenborg E, Nyman T, Virkamäki A, Funahashi T, Matsuzawa Y, Vidal H, Hamsten A, Yki-Järvinen H. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 286: E941-E949, 2004.
53. Sutinen J, Kannisto K, Korsheninnikova E, Nyman T, Ehrenborg E, Andrew R, Wake DJ, Hamsten A, Walker BR, Yki-Järvinen H. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11β- hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 47: 1668-1671, 2004.
54. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T, Yki-Järvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 88: 1907-1910, 2003.
55. Suttmann U, Holtmannspotter M, Ockenga J, Gallati H, Deicher H, Selberg O. Tumor necrosis factor, interleukin-6, and epinephrine are associated with hypermetabolism in AIDS patients with acute opportunistic infections. Ann Nutr Metab 44: 43-53, 2000.
56. Tien PC, Grunfeld C. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 17: 27-32, 2004.
57. Van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P, Sauerwein HP. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15: 2093-2100, 2001.
58. Van der Valk M, Reiss P, van Leth FC, Ackermans MT, Endert E, Romijn JA, Heijligenberg R, Sauerwein H. Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J Clin Endocrinol Metab 87: 5066-5071, 2002.
59. Walker UA, Bickel M, Lutke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, Venhoff N, Rickerts V, Staszewski S. Evidence of nucleoside analogue reverse transcriptase inhibitor -associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 29: 117-121, 2002.
60. Yki-Järvinen H, Puhakainen I, Saloranta C, Groop L, Taskinen MR. Demonstration of a novel feedback mechanism between FFA oxidation from intracellular and intravascular sources. Am J Physiol Endocrinol Metab 260: E680-E689, 1991.
61. Yki-Järvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P, Hamsten A. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 23: 688-694, 2003.